Tag Archives: uPAR


May 22, 2018

Curasight technology contribute to fluorescent tumours will vastly improve survival for people with cancer Curasight receives funding from Innovation Fund Denmark. Curasight is partner in the Fluoguide project that received the prestigieous Grand Solutions Grant from Innovation Fund Denmark to develop uPAR targeted optical imaging to be used for guiding cancer surgeons. Curasight will contribute […]

March 1, 2018

Curasight have received US patent notification with issue date 6 February 2018 and patent number 9884131, please see attached. Curasight have provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease […]

November 21, 2017

Curasight initiates new phase II study within Prostate Cancer for risk stratification Prostate cancer is one of the most frequent types of cancer in men. The characteristics of the disease varies significantly among patients where some have an indolent type of cancer, from which they will never experience symptoms while others have highly aggressive malignant […]